Pharmaceutical Market Israel,Belarus,Finland and Moldova Report At Researchmoz.us

Researchmoz presents this most up-to-date research on"Latest Research On Pharmaceutical Market Israel,Belarus,Finland and Moldova Report At Researchmoz.us". The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

The Pharmaceutical Market: Israel http://www.researchmoz.us/the-pharmaceutical-market-israel-report.html

Although Israel claims its very efficient healthcare system means it does not need to spend as much of its GDP on provision (some 7.6% was spent on this purpose in 2011), in reality the government's fiscal austerity and sick funds traditionally keep the most expensive innovative drugs and treatments unavailable. Additionally, as healthcare providers are prohibited from taking on debt, the shortage means that cheaper generics and low staff salaries have to be used to control overall costs, which often comes at the expense of services provided to patients. However, the recent ruling means that the state must increase payments to healthcare providers in order to account for rising costs, which provide some upside risks to healthcare forecasts. The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Belarus http://www.researchmoz.us/the-pharmaceutical-market-belarus-report.html

We remain largely pessimistic about the Belarus' pharmaceutical market development in the short term at least. While the government remains committed to boosting domestic pharmaceutical output over the coming years, with authorities in manufacturing joint venture (JV) discussions with a number of countries, the devalued rouble, high inflation and weak household consumption will continue to constrain both volume and value of medicines consumed in the country. We also note increased political and also economic risks, as the country aligns itself away from the European Union (EU).The Pharmaceutical risk/reward rating (RRR) score for Belarus worsened in Q113, largely on account of high levels of inflation and the corresponding weak growth in US dollar terms. The country remains viewed as one of the least attractive pharmaceutical markets in Central and Eastern Europe (CEE), ranking 18th out of 20 countries surveyed regionally. Risks also remain elevated, both on the political and economic fronts.

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Finland http://www.researchmoz.us/the-pharmaceutical-market-finland-report.html

The macroenvironment for the Finnish pharmaceutical industry is improving.Politically, the new six-party coalition is larger and represents a broader spectrum of opinion than is usual, which could make it unstable. However, the Economist Intelligence Unit (EIU) believes that it will last out its four-year term. Economically, recovery from the downturn is stalling due to the euro area debt crisis. Legally, Finland remains on the USTR’s Watch List in 2011 due to concerns over patent protection. Demographically, Finland has one of the largest proportions of population over the age of 65 in Western Europe. Latest projections expect that the population aged 65 and over will constitute more than one-fifth of the total population by 2017. The ageing population means that healthcare is increasingly focused on preventative care.

The Finnish government has introduced several cost-containment measures in recent years in an effort to curb rising healthcare costs. One of the latest affecting the pharmaceutical market in Finland is a reference pricing system. It is hoped that the new system will reduce the use of expensive pharmaceutical products, thus lowering the costs for patients and reducing the pressure to raise health insurance payments. Generic substitution in Finland has been extended to include products with an analogy process patent. As a result, generic substitution will be more effective in terms of saving money, but Finnish manufacturers of patented original products now enter generic price competition several years before product patents expire in other European countries. 

The Pharmaceutical Market: Moldova http://www.researchmoz.us/the-pharmaceutical-market-moldova-report.html

Given the high level of reliance on out-of-pocket payments, the growth of the Moldova's pharmaceutical market is expected to be shaped by the prevailing economic conditions, both at home and abroad, on account of the importance of remittances to the country's GDP. For 2012, we expect the market's value to increase at a local currency rate of 6.7%, although this will translate into negative US dollar growth, on the back of a weak leu .

Moldova's Pharmaceutical Risk/Reward Rating (RRR) score, which assesses the country's attractiveness to multinational drugmakers, remains unchanged at 41.8 for Q1 13. The score places the country second from the bottom in the regional matrix assessing 20 key markets in Central and Eastern Europe. Moldova's risks and rewards are relatively evenly balanced, although both remain considerably lower than the regional averages.

For More Information Kindly Contact:
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
Blog: http://deepmarketresearchreports.blogspot.com
word press : http://marketresearchtopix.wordpress.com